SMAD7 and osteosarcoma: In vivo experiments, using molecular (overexpression of the Smad inhibitor, Smad7) and pharmacological (SD-208 and/or halofuginone) approaches, have demonstrated that TGF-βs affect the development of lung metastases in osteosarcoma (50, 67).